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Background: Irritative voiding symptoms are common in elderly men and following
prostate radiotherapy.There is limited clinical data on the impact of hypofractionated treat-
ment on irritative voiding symptoms.This study sought to evaluate urgency, frequency, and
nocturia following stereotactic body radiation therapy (SBRT) for prostate cancer.
Methods: Patients treated with SBRT monotherapy for localized prostate cancer from
August 2007 to July 2011 at Georgetown University Hospital were included in this study.
Treatment was delivered using the CyberKnife® with doses of 35–36.25 Gy in five frac-
tions. Patient-reported urinary symptoms were assessed using the International Prostate
Symptom Score (IPSS) before treatment and at 1, 3, 6, 9, and 12 months post-treatment
and every 6 months thereafter.
Results: Two hundred four patients at a median age of 69 years received SBRT with a
median follow-up of 4.8 years. Prior to treatment, 50.0% of patients reported moderate
to severe lower urinary tract symptoms (LUTS) and 17.7% felt that urinary frequency was
a moderate to big problem. The mean prostate volume was 39 cc and 8% had prior pro-
cedures for benign prostatic hyperplasia. A mean baseline IPSS-irritative (IPSS-I) score of
4.8 significantly increased to 6.5 at 1 month (p<0.0001), however returned to baseline at
3 months (p=0.73). The IPSS-I score returned to baseline in 91% of patients by 6 months
and 96% of patients by 2 years. Transient increases in irritative voiding symptoms were
common at 1 year.The mean baseline IPSS-I score decreased to 4.4 at 24 months (p=0.03)
and 3.7 at 36 months (p<0.0001). In men with moderate to severe LUTS (IPSS≥8) at base-
line, the mean IPSS-I decreased from a baseline score of 6.8–4.9 at 3 years post-SBRT.This
decrease was both statistically (p<0.0001) and clinically significant (minimally important
difference=1.45). Only 14.6% of patients felt that urinary frequency was a moderate to
big problem at 3 years post-SBRT (p=0.23).
Conclusion:Treatment of prostate cancer with SBRT resulted in an acute increase in irrita-
tive urinary symptoms that peaked within the first month post-treatment. Irritative voiding
symptoms returned to baseline in the majority of patients by 3 months post-SBRT and
were actually improved from baseline at 3 years post-SBRT.
Keywords: prostate cancer, SBRT, CyberKnife, IPSS, irritative, overactive bladder
BACKGROUND
Irritative voiding symptoms are a common problem of male aging
(1). In men >75 years old, the prevalence of these symptoms
may be as high as 40% (2). Comorbidities may increase the risk
Abbreviations: ADT, androgen deprivation therapy; BED, biologically effective
dose; BPH, benign prostatic hyperplasia; CT, computed tomography; CTV, clinical
target volume; DVH, dose-volume histogram; EPIC, expanded prostate index com-
posite; EQD2, equivalent dose in 2-Gy fractions; GTV, gross target volume; Gy, gray;
IMRT, intensity modulated radiation therapy; IPSS, international prostate symptom
score; IRB, institutional review board; LUTS, lower urinary tract symptoms; MID,
minimally important difference; MR, magnetic resonance; PTV, planning target vol-
ume; QoL, quality of life; SD, standard deviation; SBRT, stereotactic body radiation
therapy.
of irritative voiding symptoms (3). They commonly develop or
worsen following prostate external beam radiation therapy (EBRT)
and may adversely affect a patient’s quality of life (4, 5). Patients
report the development of urinary urgency, urinary frequency, and
nocturia days to weeks after the start of treatment and generally
resolve weeks to months following completion of EBRT. Treat-
ment related factors such as utilization of brachytherapy (6) may
impact the risk of irritative voiding symptoms. Anti-cholinergic
medications may decrease these symptoms (6), but are commonly
discontinued due to associated dry mouth and constipation (7).
Urinary urgency is defined as the complaint of a sudden com-
pelling desire to pass urine, which is difficult to defer (8). Urgency
may promote urinary incontinence in patients with pelvic floor
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muscle weakness and/or poor mobility. Urinary frequency and
nocturia may increase by reducing voiding intervals (9). Noc-
turia is defined as a self-report of two or more voiding episodes
nightly (10, 11). It causes sleep loss, daytime fatigue, and depres-
sion, which adversely affects an individual patient’s quality of life
(12). In the elderly, nocturia may even increase the incidence of
falls (13, 14).
Stereotactic Body Radiation Therapy (SBRT) is a safe and effec-
tive treatment for clinically localized prostate cancer (15–19). The
larger dose per fraction utilized in SBRT offers the potential radio-
biological benefits of hypofractionation (20). The low PSA nadirs
obtained with SBRT (21) suggest it is an ablative procedure, which
eradicates both cancerous and normal epithelium. The size of the
prostate decreases by 35% within the first 2 years following the
completion of SBRT (22). Initial reports suggest that the incidence
of acute irritative voiding symptoms following SBRT is compara-
ble to other external radiotherapy modalities, and may be less than
brachytherapy (15–17). The goal of this study is to report the inci-
dence and prevalence of irritative voiding symptoms following
SBRT for clinically localized prostate cancer.
MATERIALS AND METHODS
PATIENT SELECTION
Georgetown University Hospital established its Prostate SBRT
Program in 2006. As of June 2014, 750 prostate cancer patients
have been treated with SBRT. At the inception of the program,
a prospective database was established to record baseline patient
characteristics. At each follow-up visit, toxicity and quality of life
data have also been prospectively collected and recorded. Patients
eligible for this study had SBRT without supplemental conven-
tional radiation therapy for clinically localized prostate cancer and
a minimum of 3 years of follow-up. Internal Review Board (IRB)
approval was obtained for retrospective review of the database.
SBRT TREATMENT PLANNING AND DELIVERY
Stereotactic body radiation therapy treatment planning and deliv-
ery were conducted as previously described (23, 24). Briefly, four
to six stranded gold fiducials (1013-2-2, Best Medical Interna-
tional, Inc., Springfield, VA, USA) were placed into the prostate
with two to three needle applicators via a transrectal or transper-
ineal approach. Fused computed tomography (CT) and magnetic
resonance (MR) images were used for treatment planning. The
clinical target volume (CTV) included the prostate and the prox-
imal seminal vesicles. The planning target volume (PTV) equaled
the CTV expanded 3 mm posteriorly and 5 mm in all other dimen-
sions. The prescription dose was 35–36.25 Gy to the PTV delivered
in five fractions of 7–7.25 Gy over 1–2 weeks. The prescription
isodose line was limited to ≥75%, which limited the maximum
prostatic urethra dose to 133% of the prescription dose. Blad-
der volume receiving 37 Gy was limited to <5 cc. The bladder
dose-volume histogram (DVH) goals were for <40% of the blad-
der volume to receive 50% of the prescribed dose and <10% to
receive 100% of the dose. The membranous urethra was contoured
and evaluated with DVH analysis during treatment planning using
Multiplan (Accuray Inc., Sunnyvale, CA, USA). The DVH goal was
for <50% of the membranous urethra to receive 37 Gy. To mini-
mize the risk of local recurrence, the dose to the prostatic urethra
was not constrained (25). Prostate position was verified during
treatment using paired, orthogonal x-ray images (26).
FOLLOW-UP AND STATISTICAL ANALYSIS
Prospective quality of life data was obtained on the first day
of SBRT treatment and during routine follow-up visits every
3 months for the first year and every 6 months for the second
and third years. Patient-reported irritative voiding symptoms were
assessed via the International Prostate Symptom Score (IPSS), a
validated questionnaire where higher scores indicate more severe
symptoms (27). The IPSS includes three questions related to irri-
tative voiding symptoms (frequency, urgency, and nocturia). For
the frequency and urgency questions, the responses were grouped
into four clinically relevant categories (never, less than half the
time, half or more than half the time, and almost always). For
the nocturia question, the responses were grouped into four clin-
ically relevant categories (none, 1 time, 2 times, and ≥3 times).
Table 1 | Baseline patient and treatment characteristics.
Patients
(N =204) (%)
Age (y/o) Median 69 (48~90)
Age≤60 12.7
60<Age≤70 46.6
Age>70 40.7
Race White 54.4
Black 38.7
Other 7.8
Charlson comorbidity index CCI=0 65.2
CCI=1 21.1
CCI≥2 13.7
Body mass index (BMI) Median 27.60 (15.02–44.96)
BMI≥30 30.5
Partner status Married or partnered 76.0
Not partnered 24.0
Employment status Working 48.0
Not working 52.0
Median prostate volume (cc) Median 39 (11.6–138.7) cc
Procedure for BPH 7.8
α1A Inhibitor usage 27.9
Risk groups (D’Amico’s) Low 39.7
Intermediate 52.0
High 8.3
ADT 14.2
SBRT dose 36.25 Gy 87.7
35 Gy 12.3
Baseline IPSS score Median=7.5 (0–33)
Mild (0–7) 50.0
Moderate (8–19) 43.6
Severe (≥20) 6.4
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As previously reported, nocturia was defined as urinating two or
more times per night (2). The IPSS-irritative (IPSS-I) subscore
has been previously defined as the sum of the scores for questions
2, 4, and 7 (28). Overall IPSS-I scores range from 0 to 15. IPSS-I
resolution was defined as a return to within one point of the base-
line score (29). Bother with urinary frequency was assessed via
Question 4e of the Expanded Prostate Index Composite (EPIC)-
26 (30), for which responses were grouped into three clinically
relevant categories (no problem, small problem, and moderate to
big problem).
Wilcoxon signed-rank test and Student t -test were used to
assess the differences in ongoing toxicity and quality of life scores
in comparison to baseline. To limit the effect of attrition bias,
statistical analysis was limited to time points in which ≥80% of
patient data were available. Sample medians and ranges were used
to describe continuous variables. Actuarial likelihood estimates for
time to IPSS-I resolution were determined using the Kaplan–Meier
method. To statistically compare changes between time points,
the levels of responses were assigned a score and the significance
of the mean changes in the scores was assessed by the Wilcoxon
signed-rank test. Binary logistic regression was used in the multi-
variate analysis to search for possible predicting factors for IPSS-I
improvement. The endpoint for this analysis was an IPSS-I score at
least one point lower than baseline at 3 years post-SBRT. Baseline
characteristics including age, race, Charlson Comorbidity Index
(CCI), risk group, partner status, work status, prostate volume,
baseline α1A inhibitor use, baseline androgen deprivation ther-
apy (ADT) use, previous history of transurethral resection of the
prostate (TURP), and treatment dose were included as variables in
the logistic regression model. The minimally important difference
(MID) in IPSS-I score was defined as a change of one-half standard
deviation (SD) from the baseline (31). A non-paired Student t -test
was used to determine if the magnitude of changes in the IPSS-I
score was significantly different between men with baseline mild
lower urinary tract symptoms (LUTS) (IPSS< 8) and moderate
to severe LUTS (IPSS≥8) (32).
RESULTS
From February 2008 to July 2011, 204 prostate cancer patients were
treated per our institutional SBRT monotherapy protocol with a
median follow-up of 4.8 years. They were ethnically diverse with a
median age of 69 years (range, 48–90 years) (Table 1). The median
prostate volume was 39 cc and 8% of patients had prior procedures
for benign prostatic hyperplasia (BPH). The median baseline IPSS
was 8 and 28% of patients were using alpha-antagonists prior to
SBRT. By D’Amico classification, 40% patients were low-, 52%
intermediate-, and 8% high-risk. Fourteen percent of patients
initiated ADT 3 months prior to the start of SBRT and for a
mean duration of 5.5 months and a median duration of 3 months.
Eighty-eight percent of patients were treated with 36.25 Gy in five
7.25 Gy fractions. The majority of patients had irritative voiding
symptoms prior to treatment with a mean baseline IPSS-I score of
4.8 (Table 2; Figure 1A). At 1 month post-SBRT, the mean IPSS-I
significantly increased to 6.5 (p< 0.0001), but returned to base-
line at 3 months (p= 0.7319) (Table 2; Figure 1A). This increase
was of borderline clinical significance (MID= 1.5). The median
time to IPSS-I normalization was 3 months (Figure 2). The IPSS-I
returned to baseline in 91% of patients by 6 months and 96% of
patients by 2 years. At 2 years, the mean IPSS-I was close to base-
line at 4.4 (p< 0.03). The mean IPSS-I significantly decreased from
a baseline score of 4.8–3.7 (p< 0.0001) at 3 years post-SBRT. At
3 year post-SBRT, 59% of patients had an IPSS-I score that was less
than their baseline. No baseline patient or treatment characteris-
tics were significantly associated with improved irritative voiding
symptoms on univariate or multivariate analysis 3 years follow-
ing SBRT (data not shown). Alpha-antagonist utilization peaked
Table 2 | IPSS-irritative subscores.
Start 1 3 6 9 12 18 24 30 36
(A)
Mean 4.76 6.53 4.72 4.75 5.10 5.14 4.53 4.40 4.29 3.71
p-Value <0.0001* 0.73 0.78 0.29 0.12 0.21 0.03* 0.003* <0.0001*
STDEV 3.08 3.25 2.86 2.91 3.24 3.35 3.23 3.31 3.10 3.40
MID 1.54
(B)
Mean 2.69 5.49 3.40 3.64 3.85 4.11 3.55 3.20 3.07 2.48
p-Value <0.0001* 0.0004* 0.0013* 0.0002* <0.0001* 0.0042* 0.02* 0.23 0.43
STDEV 1.42 2.78 2.04 2.23 2.51 3.08 2.45 2.40 2.15 2.22
MID 0.71
(C)
Mean 6.80 7.56 6.01 5.81 6.29 6.12 5.52 5.49 5.41 4.91
p-Value 0.014* 0.001* 0.002* 0.106 0.027* 0.0002* <0.0001* <0.0001* <0.0001*
STDEV 2.91 3.37 2.95 3.09 3.41 3.32 3.61 3.66 3.42 3.90
MID 1.45
(A) Mean IPSS-I patient-reported scores at baseline and during follow-up.
(B) Mean IPSS-I patient-reported scores with baseline IPSS score <8 for 102 patients.
(C) Mean IPSS-I patient-reported scores with baseline IPSS score ≥8 for 102 patients.
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FIGURE 1 | IPSS-irritative subscores over the 36 months of follow-up
stratified by baseline LUTS. (A) Mean IPSS-irritative score for all patients.
(B) Mean values of patients with a mild baseline LUTS (IPSS<8, n= 102).
(C) Mean values of patients with a moderate to severe baseline LUTS
(IPSS≥8, n= 102). Changes in scores that are statistically significant
different from baseline are marked with an asterisk (*). Thresholds for
clinically significant changes in scores (1/2 standard deviation above and
below the baseline) are marked with dashed lines. IPSS-irritative scores
range from 0 to 15 with lower values representing a more favorable
outcome.
1 month post-treatment, at 53% patient utilization, then slowly
decreased to near baseline, with 32% of patients reporting use at
3 years (Figure 2B).
Individual irritative voiding symptoms (frequency, urgency,
and nocturia) followed a similar trend (Table 3). At 1 month post-
SBRT, frequency significantly increased (p< 0.0001), but returned
to baseline at 3 months (p= 0.14) (Table 3A). By 2 years, frequency
had actually declined to below baseline (p= 0.002). Likewise,
urgency increased significantly at 1 month and returned to base-
line at 3 months (p= 0.64) (Table 3B). However, a second late
protracted increase in urgency occurred between 9 and 18 months.
Urgency returned to near baseline by 2 years post-SBRT. Simi-
larly, nocturia increased transiently at 1 month and then again at
12 months (Table 3C; Figure 3). The pre-treatment and 3-year
nocturia rates were similar.
Next, we assessed the impact of SBRT on irritative voiding
symptoms 3 years following treatment on men with baseline mild
(IPSS< 8, 102 men) LUTS versus moderate to severe (IPSS≥ 8,
102 men) LUTS (Tables 2B,C; Figures 1B,C) (32). In men with
mild LUTS at baseline, the mean IPSS-I returned to near baseline
by 3 years post-SBRT (Table 2B; Figure 1B). In men with moderate
to severe LUTS at baseline, the mean IPSS-I significantly decreased
from a baseline score of 6.8 to 4.9 at 3 years post-SBRT (Table 2C;
Figure 1C). This decrease was both statistically (p< 0.0001) and
clinically significant (MID= 1.45).
At baseline, 63.1% of our cohort reported some level of bother
due to urinary frequency with 17.7% of patients feeling it was
a moderate to big problem (Table 4). At 1 month post-SBRT,
moderate to big bother with urinary frequency increased to 28%
(p< 0.0001), but reduced to 15.2% at 3 months (p= 0.7251).
Although bother declined quickly, a second late transient increase
in bother occurred at 12 months (Table 4). Despite this increase,
only 14.6% of patients felt that weak urine stream and/or
incomplete emptying was a moderate to big problem at 3 years
post-SBRT (p= 0.2303).
DISCUSSION
Urinary toxicity following prostate radiotherapy involves both
obstructive and irritative symptoms. Irritative voiding symptoms
are more bothersome (4), yet they remain understudied. A bet-
ter understanding of the pattern of irritative voiding symptoms
following SBRT would enable clinicians to provide more realistic
expectations to patients (33). In this study, we utilized validated
QoL questionnaires to comprehensively evaluate irritative voiding
symptoms following SBRT (27, 34).
An acute increase in irritative voiding symptoms occurs in
most patients post-SBRT. It is believed to occur secondary to
inflammation of the bladder neck/urethra. This study shows
that SBRT acutely increases all irritative voiding symptoms (fre-
quency, urgency and nocturia) in a similar manner. Furthermore,
our results appear comparable to those reported for IMRT and
brachytherapy (4). Irritative voiding symptoms may occur sec-
ondary to detrusor overactivity and could be treated as such
(35). However, antimuscarinics are not routinely prescribed at
our institution due to their known side effects and the potential
risk of increased post-void residuals (36). Alternative approaches
to managing acute irritative voiding symptoms post-SBRT should
be explored.
Nocturia is the most bothersome LUTS (37). Nocturnal void-
ing as little as twice per night is associated with decreased quality
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FIGURE 2 | Irritative voiding symptoms following SBRT for prostate cancer. (A) Time to IPSS-I resolution was determined by the number of months it took
for the IPSS-I score to return to within one point of the baseline score. (B) Percent of patients utilizing alpha-antagonists at each time point.
Table 3 | Patient-reported responses to IPSS-irritative voiding questions at baseline and following SBRT for prostate cancer, recorded as the
percent of the patient cohort.
Start 1 3 6 9 12 18 24 30 36
A. Frequency
Never 17.7% 11.5% 17.7% 16.1% 13.5% 17.4% 15.8% 21.7% 19.3% 21.7%
Less than half 52.7% 44.5% 62.6% 60.2% 57.8% 51.7% 60.6% 57.7% 58.5% 52.2%
Half or more 24.1% 37.5% 16.7% 21.5% 23.2% 27.0% 21.2% 16.0% 19.3% 23.6%
Almost always 5.4% 6.5% 3.0% 2.2% 5.4% 3.9% 2.4% 4.6% 2.9% 2.5%
Wilcoxon <0.0001* 0.1358 0.1787 0.8268 0.9429 0.093 0.0022* 0.0066* 0.1198
N= 203 200 198 186 185 178 165 175 171 157
B. Urgency
Never 41.9% 21.0% 35.5% 31.2% 31.4% 32.0% 33.5% 39.4% 35.1% 39.5%
Less than half 41.9% 47.0% 47.2% 50.5% 48.6% 45.5% 48.2% 42.3% 46.8% 43.3%
Half or more 10.8% 25.0% 12.2% 14.5% 13.5% 16.3% 12.2% 11.4% 12.9% 10.2%
Almost always 5.4% 7.0% 5.1% 3.8% 6.5% 6.2% 6.7% 6.9% 5.3% 7.0%
Wilcoxon <0.0001* 0.6357 0.0943 0.0738 0.0287* 0.1207 0.6797 0.6818 0.5435
N= 203 200 198 186 185 178 165 175 171 157
C. Nocturia
None 9.4% 5.0% 9.6% 7.5% 7.6% 10.1% 9.1% 9.1% 9.9% 6.4%
1 time 38.4% 21.0% 31.3% 39.8% 35.1% 28.7% 37.0% 33.7% 36.3% 38.9%
2 times 25.6% 31.0% 34.8% 29.0% 28.6% 34.3% 30.3% 32.6% 30.4% 33.8%
≥ 3 times 26.6% 43.0% 24.2% 23.7% 28.6% 27.0% 23.6% 24.6% 23.4% 21.0%
Wilcoxon <0.0001** 0.5314 0.5303 0.2733 0.087 0.9624 0.6498 0.797 0.8063
N= 203 200 198 186 185 178 165 175 171 157
(A) Frequency (IPSS question 2) defined as how often a patient had to urinate within 2 hours of previously urinating.
(B) Urgency (IPSS question 4) defined as how often a patient found it difficult to postpone urination.
(C) Nocturia (IPSS question 7) defined as how often a patient needed to get up to urinate at night.
of life and may increase the risk of falls (11–13) To prevent
falls and their associated morbidity, patients should be educated
about their increased incidence following prostate radiation ther-
apy. This study confirms the high incidence of baseline nocturia
in elderly men with prostate cancer (38), while also showing a
transient increase in nocturia at one month and twelve months
post-treatment.
Due to its effectiveness and convenience, brachytherapy is
a common treatment option for prostate cancer. Post-implant
irritative voiding symptoms are a common toxicity that may
impact long-term quality of life. IPSS resolution following
brachytherapy varies from months to years (29, 39, 40). Our mean
IPSS-I scores returned to baseline within 3 months post-SBRT. A
minority of patients experienced a transient increase in irritative
voiding symptoms greater than six months after the completion of
SBRT. As with brachytherapy, late urinary symptom flare (41–43)
occurred in a minority of our patients and resolved with con-
servative management. Knowledge of this late transient increase
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Table 4 | Bother with frequency at baseline and following SBRT for prostate cancer (question 4e of the EPIC-26).
Start 1 3 6 9 12 18 24 30 36
No problem 36.9% 17.5% 35.9% 34.9% 32.4% 31.5% 39.4% 42.3% 39.8% 42.0%
Very small–small problem 45.3% 54.5% 49.0% 50.0% 50.3% 48.9% 44.8% 44.0% 44.4% 43.3%
Moderate—big problem 17.7% 28.0% 15.2% 15.1% 17.3% 19.7% 15.8% 13.7% 15.8% 14.6%
Wilcoxon <0.0001* 0.7251 0.9337 0.4439 0.1663 0.6522 0.1859 0.5768 0.2303
N= 203 200 198 186 185 178 165 175 171 157
Patients were stratified into three groups: no problem, very small to small problem, and moderate to big problem. The percentage of patients in each group at each
time point is depicted in the chart over 3 years.
FIGURE 3 | Nocturia following SBRT for prostate cancer: (nocturia was
defined as urinating ≥2 times per night).
in irritative voiding symptoms will enable clinicians to address
patient concerns.
Bother is defined as the degree of interference or annoyance
caused by a symptom (39, 44). Similar to other radiation modal-
ities, bother with urinary frequency plateaued at one month fol-
lowing treatment with 28% of men reporting it to be a moderate
to big problem. This change compares favorably to the change
reported at two months with conventionally fractionated EBRT
(34%) and brachytherapy (45%) (4). As seen with EBRT, this
increase in bother was transient and returned to baseline by
3 months post-SBRT. A second increase in bother occurred twelve
months post-SBRT with 19.7% of patients reporting moderate to
big bother at this time point. This change is comparable to that
reported at twelve months with brachytherapy (20%) (4). Unlike
brachytherapy, bother following SBRT returned to near baseline
by 2 years (7.1 vs. 20%) and improved over baseline at 3 years.
Compared with prostatectomy, radiation therapy causes less
incontinence at the expense of increased acute irritative void-
ing symptoms. However, this study shows that SBRT, like radical
prostatectomy (45), may prevent age dependent increases in late
irritative voiding symptoms. As seen following prostatectomy, men
with moderate to severe LUTS benefited the most (45). Radi-
cal prostatectomy has been shown to improve irritative voiding
symptoms within the first year following treatment (4, 46, 47). It
has been hypothesized that this is secondary to relief of prosta-
tic obstruction. SBRT is ablative, with a decrease in prostate size
seen within the first 3 years following treatment (22). Etiology of
reduced irritative voiding symptoms 3 years post-SBRT is unclear,
but may be due to prostate size reduction associated with SBRT
treatment.
There were several limitations to this study. The EPIC-26
assesses bother associated with frequency but not bother related to
urgency and nocturia (30). However, due to the high correlation
between bother associated with these symptoms, it is unlikely that
this would impact our conclusions. In addition, alternative mech-
anisms could explain the late improvement in irritative voiding
symptoms such as prostate size reduction secondary to ADT and
increased alpha antagonist usage (48). However, ADT usage was
unlikely the main cause of improvement, as <14% of patients
received it with a median duration of only 3 months and a total of
three patients, 1.5%, receiving ADT for longer than 6 months. In
addition, the baseline QOL assessment took place prior to treat-
ment, on the first day of SBRT, 3 months after the initiation of ADT
(49). Likewise, pre-treatment alpha antagonist usage was high and
returned to baseline by 2–3 years post-SBRT (50).
CONCLUSION
Stereotactic body radiation therapy treatment resulted in an
acute increase in irritative voiding symptoms that peaked at one
month post-treatment. These symptoms returned to baseline in
the majority of patients by 3 months. Patients with moderate to
severe LUTS can expect an improvement in their baseline irritative
voiding symptoms years after treatment. Bother with urinary fre-
quency was at baseline 2 years post-SBRT and improved by 3 years
post-SBRT.
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